NuCana (NCNA) discontinues Phase II NuTide:323 colorectal cancer study

Scotland-based biotech NuCana has announced that it is discontinuing its NuTide:323 study (NCT05678257).

NuTide:323 was an open-label, dose/schedule optimisation study evaluating the efficacy of NuCana’s NUC-3373 ProTide in combination with leucovorin, irinotecan and bevacizumab (NUFIRI+bev).

• NuCana plc's American Depositary Shares (ADSs) began trading on October 2, 2017. 
• NuCana plc is a clinical-stage biopharmaceutical company that develops new medicines to treat cancer. The company was founded in 1997 by Hugh Stephen Griffith and Christopher Barry Wood and is headquartered in Edinburgh, Scotland. NuCana's ProTide technology transforms widely prescribed chemotherapy agents into safer and more effective medicines.
• GlobalData’s pharmaceutical database shows that NuCana has 13 ProTides in its drug development pipeline, in indications including ovarian cancer, non-small cell lung cancer, and acute lymphocytic leukaemia. 
  
• https://www.nucana.com/

 

 

 

 

Mediwound (MDWD) : 10-year performance

• ticker: MDWD
  

Momentus Space (MNTS) : 3-year performance

• Momentus Space began trading on NASDAQ on August 13, 2021 under the ticker MNTS. The company's SPAC was completed on that day with an implied valuation of $567 million.
• Momentus Space is a commercial space company that provides in-space infrastructure services, including transportation, hosted payloads, and in-orbit services. 

ticker: MNTS
 

WideOpenWest (WOW): 7-year performance

 ticker: WOW

Mereo BioPharma (MREO) : 5-year performance

• Mereo BioPharma (MREO) was founded in March 2015 to fund and develop high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies.
• It acquired a portfolio of three product candidates from Novartis in July 2015 and a fourth product from AstraZeneca in October 2017. In April 2019, Mereo merged with OncoMed, a Nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing novel oncology products.
• OncoMed Pharmaceuticals (OMED) had its IPO on Jul 17, 2013. The company sold 4.8 million shares at $17, above the $14 to $16 shares range laid out earlier. The offering raised $82 million.

Asset Entities (ASST) : 18-month performance

Asset Entities Inc., a technology company, provides social media marketing and content delivery services across Discord, TikTok, and other social media platforms. It designs, develops, and manages servers for communities on Discord. 

• Sector: Communication Services
• Industry: Internet Content & Information
• Full Time Employees: 11
• Founded in 2020 
• Based in Dallas, Texas
• https://www.assetentities.com

Autozi Internet Technology (AZI) began trading on the Nasdaq on Wed 28 Aug 24

Autozi Internet Technology (Global) Ltd., through its subsidiaries, provides professional one-stop automotive products and services through online and offline channels in the People's Republic of China. It sells new cars, and auto parts and accessories, as well as offers automotive insurance related services. 

• Sector(s): Consumer Cyclical
• Industry: Auto & Truck Dealerships
• Full Time Employees: 83
• Founded in 2010 
• HQ in Beijing, China
• https://www.autozi.com

 

Autozi priced its initial public offering (the "Offering") of 2,500,000 Class A ordinary shares at a public offering price of US$4 per Class A ordinary share for total gross proceeds of approximately $10 million, before deducting underwriting discounts and commissions and offering expenses.

 

IPOs this week : Aug 26 - 30, 24 (wk 35)

IPOs expected to price

• No new IPOs are expected to start trading in the U.S. 

IPO lockup expirations

• The IPO lockup period expires for a block of shares of SolarMax Technology (NASDAQ:SMXT).

IPOs this week : Aug 19 - 23, 24 (wk 34)

 

WeRide – Guangzhou, China, 6.5 million shares, priced at $15.50-$18.50, managed by Morgan Stanley JP Morgan. Proposed Nasdaq symbol WRD. Business: Chinese developer of autonomous vehicle systems and software.

YHN Acquisition I – Hong Kong, 6 million shares, priced at $10, managed by Lucid Capital Markets. Proposed Nasdaq symbol YHNAU. Business: Blank check company led by executives from boutique SPAC firm Norwich Capital.

XCharge – Beijing, 3.3 million shares, priced at $6-$8, managed by Tiger Brokers Huatai. Proposed Nasdaq symbol XCH. Business: Provides DC fast chargers and related EV technology out of China and Europe.

Cuprina Holdings – Singapore, 3.8 million shares, priced at $4, managed by Network 1. Proposed Nasdaq symbol CUPR. Business: Singapore-based provider of skincare and chronic wound care products.

Trident Digital Tech – Singapore, 1.8 million shares, priced at $5-$7, managed by WallachBeth Revere Sec.. Proposed Nasdaq symbol TDTH. Business: Provides business consulting, marketing, and IT services to SMEs in Singapore.

Reitar Logtech – Hong Kong, 2.1 million shares, priced at $4-$5, managed by Cathay Securities. Proposed Nasdaq symbol RITR. Business: Provides design and other services to the logistics industry in Hong Kong.

Powell Max – Hong Kong, 1.7 million shares, priced at $4-$6, managed by WallachBeth Revere Sec.. Proposed Nasdaq symbol PMAX. Business: Provides financial communication services in Hong Kong.

IPO quiet period expirations

The quiet period ends for 

• Lineage (LINE), 
• OneStream (OS), and 
• LATAM Airlines Group S.A. (LTM) to free up analysts to post ratings.

Actuate Therapeutics (ACTU) began trading on the Nasdaq on Tue 13 Aug 24

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. 

The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 11
• Incorporated in 2015 
• Based in Fort Worth, Texas
• https://actuatetherapeutics.com
• Ticker: ACTU
  

IPOs this week : Aug 12 - 16, 24 (wk 33)

IPOs expected to price

• YXT.COM Group Holding (YXT) is the only company expected to launch an IPO in the U.S. this week. The Chinese cloud-based digital corporate education platform business is looking to raise $50M. 

IPO quiet period expirations

IPO quiet periods expire on 

• Ardent Health Partners (ARDT), 
• TWFG (TWFG), and 
• Artiva Biotherapeutics (ARTV) to free up analysts to post ratings. 

IPO lockup expirations

The IPO lockup period expires for blocks of shares of Sacks Parente Golf (SPGC) and Chromocell Therapeutics (CHRO).

Fiverr International (FVRR) : 5-year performance

 ticker: FVRR

Recursion Pharmaceuticals (RXRX) : 3-year performance

 

ThredUp (TDUP) reported earnings on Mon 5 Aug 24 (a/h)

ticker: TDUP 

 ** charts after earnings **

OAKLAND, Calif. (AP) — OAKLAND, Calif. (AP) — ThredUp Inc. (TDUP) on Monday reported a loss of $13.6 million in its second quarter.

The Oakland, California-based company said it had a loss of 13 cents per share.

The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 10 cents per share.

The online seller of secondhand clothing posted revenue of $79.8 million in the period, which also fell short of Street forecasts. Four analysts surveyed by Zacks expected $82.6 million.

For the current quarter ending in September, ThredUp said it expects revenue in the range of $69 million to $71 million.

The company expects full-year revenue in the range of $298 million to $302 million.

IPOs this week : Aug 5 - 9, 24 (wk 32)

IPOs expected to price

No new IPOs are expected to start trading next week. 

IPO lockup expirations

IPO lockup periods expire on blocks of shares of 

• BBB Foods (TBBB), 
• Metagenomi (MGX), and 
• Telomir Pharmaceuticals (TELO).